The biotech exec speaks about the global launch of his firm’s lead product, Duchenne drug Translarna.
Novartis’s Sandoz will kickstart its marketing plans as it awaits FDA’s decision to approve the first biosimilar in the US.
Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen’s patient-care model.
Severe flu season to test Roche’s Tamiflu; Novartis gains nod for psoriasis drug; Amgen and Kite collaborate on immunotherapy.
Merck said in November that a long-running clinical trial finally demonstrated the impact of its Zetia cholesterol-lowering treatment on cardiovascular outcomes. The results from the so-called IMPROVE-IT trial are expected to shore up Zetia/Vytorin sales, analysts said, after the first trial showing that a non-statin added to a statin reduces cardiovascular events. Doctors now may…
Pop songs about doctors get heavy rotation in BMJ; digital-health investment tally shows doubling in 2014; scientists finger bats as possible Ebola source.
The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.